Latest Annexon Biosciences News & Updates

See the latest news and media coverage for Annexon Biosciences. We track all announcements, press releases, and industry mentions in real time, all in one place.

Annexon Biosciences

Developer of C1q inhibitors for complement-driven diseases

annexonbio.com

Headquarters: South San Francisco, United States
Founded year: 2011
Company type: Public company
Number of employees: 110–200
Industry: Biotechnology & Medical Research

Last updated October 5

Latest news about Annexon Biosciences

In short: Annexon reported positive GBS data, filed an EMA application and advanced GA trials.

Company announcements

October 5 Annexon Biosciences

Annexon reports strong Phase 3 data for tanruprubart in GBS

The therapy met the primary endpoint with significant benefits over placebo and IVIg. MAA is filed in Europe.

October 2 Annexon Biosciences

Annexon Biosciences shares Phase 3 FORWARD study results

First patient outcomes for tanruprubart in GBS show improved muscle strength and disability with no new safety findings at WMS Meeting.

September 24 Annexon Biosciences

Annexon shares Phase 3 data showing Tanruprubart benefits in Guillain-Barré patients

Treatment reduced ICU days and ventilation time while improving independence and recovery rates compared to placebo.

September 24 Annexon Biosciences

Annexon presents positive Phase 2 data for Vonaprument in Geographic Atrophy

Vonaprument demonstrated significant vision preservation and structural protection compared to sham. Phase 3 ARCHER II trials are underway with results expected in late 2026.

Media coverage

September 10 Investing.com

Annexon at Cantor Fitzgerald conference: eye data, gbs progress By Investing.com

On Thursday, 10 September 2026, Annexon (ANNX) used the 12th Annual Cantor Fitzgerald Global Healthcare Conference to press its case as a complement-focused drug developer...

August 19 Healio

Vonaprument may protect from vision loss in geographic atrophy

In the phase 2 ARCHER study, vonaprument (Annexon Biosciences), formerly known as ANX007, decreased the number of patients with notable vision loss by approximately two-thirds...

August 12 Yahoo

Thousands of Americans live with this rare condition—New drug may give hope

The experimental drug could become the first approved treatment for Guillain-Barré syndrome, a paralyzing nerve disease.

August 12 Markets Insider

Annexon Reports Second Quarter 2026 Financial Results, Business Updates and Key Anticipated Milestones

Rapid, Positive Clinical Outcomes in GBS FORWARD Study Reinforce Consistency and Reproducibility of Tanruprubart Treatment Effect Demonstrated in Phase 3 and Real-World Evidence Studies; BLA...

Never miss news about Annexon Biosciences

Track Annexon Biosciences and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.

Trending companies

Discover what's making headlines across other trending companies.